Mutations in the CD40 ligand (CD40L) are responsible for human hyper immunoglobulin M (IgM) syndrome. The absence of the interaction between CD40L, expressed by T lymphocytes, and the CD40 receptor present on the surface of B cells is responsible for the inability of B cells to carry out the isotype switch from IgM to the other Ig classes. This leads to a fatal immunodeficiency for which no cure exists. For these reasons, the CD40L gene is a good candidate for gene therapy studies. To investigate the possible effects of the expression of this tightly regulated gene in vivo, we produced transgenic mice in which CD40L expression was deregulated. Widespread ectopic expression appears to be lethal. Overexpression in mature T cells is compatible with life, but in one-third of the cases, mice developed atypical lymphoid proliferations which, occasionally, progressed into frank lymphomas. Even though gene therapy is one of the most promising approaches to cure human hyper IgM syndrome, these results suggest that when we modify very tightly regulated genes such as cytokines or other growth factors, particular care has to be taken to avoid excessive stimulation of the target cells.
T he immune system is a very delicate network of positive and negative signals that allows prompt activation of selected lymphoid populations in response to stimuli; this activation can be turned off rapidly when the stimulus is no longer present. Inability to exactly regulate both activation and repression of lymphoid cells has profound effects on immune function, leading to a failure to mount adequate responses to pathogens or to excessive cell proliferation, which in turn results in autoimmune or neoplastic phenomena. In this regard, one of the best examples is given by the delicate equilibrium that underscores the action of molecules of the tumor necrosis factor-␣ (TNF-␣) superfamily and their receptors. 1, 2 Many members of the TNF superfamily exert profound effects on the immune system. In human pathology as well as in the mouse model, spontaneous mutations inactivating CD40 ligand (CD40L) and Fas receptor and its ligand have been described. [3] [4] [5] [6] [7] [8] [9] [10] In the case of CD40L, the phenotype shown by patients affected by hyper immunoglobulin M (IgM) syndrome (HIGM1), in which the CD40L is defective, is characterized by a failure of B cells to proliferate and to switch from IgM production to Ig of other isotypes. 4, 5, 6, 8, 11, 12 Conversely, in both human and mouse abnormalities of the Fas system, a lymphoproliferative and autoimmune phenotype is seen (reviewed in Refs. 13 and 14) . Although it has been demonstrated that CD40L activation can also lead to apoptosis 15 and the molecular effectors in this pathway have been identified, 2 the in vivo data suggest that the CD40 system positively affects the proliferation and function of B lymphocytes, whereas the most important role of the Fas pathway is to induce B cells to undergo apoptosis.
The CD40L mouse knockout has shown the expected phenotype, although the immune defect is not as severe as seen in humans with the same CD40L abnormality. These mice show low levels of circulating Ig isotypes and respond normally to thymus-independent antigens (Ags), but have a decreased IgM response and fail to produce an Ag-specific IgG1 response to thymus-dependent Ags. In addition, they have lymph nodes but do not develop germinal centers (GC) in response to these latter Ags. 16 -19 These results are comparable with those seen in human pathology, as a lack of GC has also been demonstrated in pathological studies from HIGM1 patients. 20 A similar phenotype is shown in CD40-deficient mice, which are unable to carry out Ig class switching or generate GC. 21, 22 However, recent data have added further complexity to the delicate equilibrium between lymphoid cell activation and death, revealing that other members of the TNF family also play a role not only in the functioning of mature lymphoid cells but also in the normal maturation of the peripheral lymphoid system as a whole. The TNF-␣, lymphotoxin ␣ (LT␣), and LT␤ genes and their receptors have been disrupted. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The results obtained demonstrate a previously unrealized role for these cytokines in peripheral lymphoid organ development. TNF-␣ Ϫ/Ϫ mice have expanded marginal zones in the spleen but are deficient in follicles and follicular dendritic cells, whereas LT␣ Ϫ/Ϫ mice show a more severe developmental defect, as they are missing peripheral lymph nodes and Peyer's patches (PP). LT␤ Ϫ/Ϫ mice have a somewhat intermediate phenotype, as they lack peripheral lymph nodes, PP, primary and secondary follicles, and follicular dendritic cells, but have mesenteric and cervical lymph nodes. Mice lacking the p75 TNF receptor (TNFR) develop lymph nodes and PP, 25 whereas mice with interrupted p55 TNFR have been reported to have normal or absent PP. 32, 38 Defective GC formation is also seen in mice after inactivation of nuclear factor-B2 and bcl-3 genes, which are also involved in TNFR signaling pathways. 39 -42 Taken together, these results suggest that unexpectedly, the TNF pathway is fundamental in peripheral lymphoid organ development, whereas, as expected, the function of the CD40 pathway is restricted to a subsequent maturation step, necessary for the formation of GC. It can be concluded that the normal architecture of peripheral lymph nodes depends upon the proper expression of the TNF family genes.
Despite the results obtained with the inactivation of TNF family genes, few data exist on the effect on peripheral lymphoid organs in the case of the overexpression or ectopic expression of these genes, although expression of TNF-␣ in pancreas islet cells has been reported to prevent autoimmune diabetes in nonobese diabetic mice, 43 whereas expression in the central nervous system caused a spontaneous inflammatory demyelinating disease. 44 In particular, as CD40L expression is so tightly regulated, it could be expected that its deregulation may lead to autoimmune phenomena, and increased expression of CD40L has indeed been reported in patients with systemic lupus erythematosus. 45 Investigation of the effects of excessive stimulation of CD40L are also warranted in another respect. Because it is a fatal disease, HIGM1 is a candidate for gene therapy; as many viral vectors contain strong viral promoters, studies in mice are needed before attempting to correct the defect in humans with vectors that have the potential to disrupt the tight regulation of CD40L.
To investigate these issues, we tried to produce transgenic mice in which the CD40L gene is under the control of ubiquitous or T-cell-restricted promoters. We found that deregulation of the CD40L is likely to be toxic during fetal development, as only one lineage could be established. Careful investigation of these mice suggests that proper CD40-CD40L interaction is necessary to maintain the homeostasis of the lymphoid population in peripheral lymph nodes, and that great attention must be paid when gene transfer with cytokines or growth factors is attempted to correct hereditary gene defects.
MATERIALS AND METHODS

DNA constructs
Murine CD40L cDNA was obtained by polymerase chain reaction (PCR) amplification of retrotranscribed spleen mRNA using the following primers: KozacF (ACAGCAT-GATAGAAACATACAGCC) and 780R (TCAGAGTTT-GAGTAAGCC). Amplification conditions (35 cycles) were as follows: 94°C for 20 seconds, 58°C for 30 seconds, and 72°C for 20 seconds. The PCR product was cloned and completely sequenced in Blue Script (Stratagene, La Jolla, Calif) plasmids.
The KozacF primer was designed to add a Kozac consensus to the 5Ј end of the cDNA. The cDNA was cloned into the PstI/XbaI sites of PGKNeo plasmid, thus obtaining the PGK-CD40L plasmid. HTLVI-CD40L was obtained by cloning a HindIII/XbaI CD40L cDNA fragment into the HindIII/XbaI sites of PGKNeo, thus obtaining the CD40LpA plasmid. The HTLVI long terminal repeat (LTR) was cloned as a HindIII/ XhoI fragment from the pU3RIII plasmid 46 into the HindIII/ SalI sites of the CD40L plasmid. Both PGK-CD40L and HTLVI-CD40L constructs were excised as XhoI fragments, purified, and used for the production of transgenic mice.
Production and characterization of transgenic mice
CD-1 albino mice were supplied by Charles River (Calco, Italy). Transgenic mice were produced by pronuclei microinjection of 1-cell stage embryos with PGK-CD40L or HTLVI-CD40L constructs. They were screened by Southern blot analysis and/or by PCR performed on tail DNA. 47 For Southern blot analysis, genomic DNA was restricted with BamHI, run on a 1% agarose gel, and blotted to a Hybond N ϩ nylon filter (Amersham, Little Chalfont, UK) in 0.4 M NaOH. The probe used for hybridization was the CD40L cDNA fragment. PCR analysis was performed using the conditions described previously.
Analysis of CD40L expression was carried out by reverse transcriptase (RT)-PCR on deoxyribonuclease-treated RNA extracted from the liver, kidney, spleen, and thymus of transgenic and control mice. RNA was extracted according to standard procedures. 48 The primers used for the amplification were HTLV1 (GACTGGGACGAACGAGTTGAG) and 419 (TCACTGTAGAACGGATGC), which are specific for the transgene expression and do not amplify the endogenous transcript. The amplification of a constitutively expressed gene, hypoxanthine phosphoribosyltransferase (HPRT), was performed using the following primer pair: HPRT1 (TGCT-CAAGGGGGGCTATAAG) and HPRT2 (TCCAACACT-TCGAGAGGTCC). The amplification conditions were as described previously.
Histopathological analysis
Mice were sacrificed, and a complete necropsy was performed. All tissues removed were partially fixed in buffered formalin, partially fresh-frozen in liquid nitrogen-precooled isopentane, and stored at Ϫ80°C. Fixed tissues were embedded in paraffin, stained with hematoxylin and eosin, and used for histological examination. Immunohistochemical stainings were performed on cryostat sections from the frozen material using the streptavidin-biotin peroxidase-conjugated technique, and the follow-ing primary monoclonal antibodies (mAbs) were applied: rat anti-mouse Mac-3 (M3/84), rat anti-mouse CD45R/B220 (RA3-6B2), hamster anti-mouse CD3⑀ (145-2C11) (all purchased from PharMingen, San Diego, Calif), and rat antimouse CD40L (kindly provided by Dr. R. Noelle, Dartmouth Medical School, Lebanon, NH); in addition, polyclonal goat anti-mouse CD40 (clone T-20; Santa Cruz Biotechnology, Santa Cruz, Calif) and goat anti-mouse CD40L (clone K-19; Santa Cruz Biotechnology) were used. As secondary antibodies (Abs), biotin-conjugated mouse anti-hamster IgG mAb (cocktail G70-204 and G94-56; PharMingen), rabbit anti-rat IgG (heavy and light), and rabbit anti-goat (Biogenex, San Ramon, Calif), adsorbed with mouse Igs (Vector Laboratories, Burlingame, Calif) were used. The chromogen reaction was developed using a solution containing 0.024% hydrogen peroxide and 0.016% diaminobenzidine tetrahydrochloride in phosphate-buffered saline (PBS) (pH 7.4). A light nuclear counterstain was performed with Meyer hematoxylin.
Fluorescence-activated cell sorter analysis
Approximately 5 ϫ 10 5 cells were incubated in 96-well, Vbottom plates (Greiner, Nurtingen, Germany) for 30 -45 minutes at 4°C in 20 L of PBS (with 1% bovine serum albumin and 0.1% sodium azide) and saturating amounts of mAb. Cells were washed two times with PBS and incubated with streptavidin-phycoerythrin for biotinylated Abs. The cells were analyzed on a FACScan (Becton Dickinson, Mountain View, Calif) using Lysis II software. Data are depicted as dot plots. The following Abs were used: CD45R/B220 (6B2), CD4 (RM4-5), CD8 (53-6.7), CD43 (S7), BP-1 (6C3), and heat stable Ag (HSA) (clone M1/69), all from PharMingen. Surface Ig (sIg)/goat anti-mouse Ig was purchased from Tago (Burlingame, Calif). Rat anti-IgM Ab was also purchased from PharMingen as a purified mouse mAb from clone G53-238.
Molecular analysis of Ig gene rearrangements
Genomic DNA was extracted from the lymph nodes, spleen, thymus, liver, kidney, and tail of transgenic mice, digested with EcoRI, run on a 0.6% agarose gel, and blotted to a Hybond N ϩ nylon filter (Amersham) in 0.4 M NaOH. The probe used for the hybridization was the joining region probe pJ11 described in Ref 49 .
RESULTS
Production and characterization of transgenic mice
Two constructs were used in the present study. The first, in which wild-type (wt) CD40L cDNA was put under the control of a phosphoglycerokinase promoter, was devised to direct CD40L expression ubiquitously. The second, in which the CD40L gene was placed under the control of the LTR of HTLVI, was expected to be expressed constitutively mainly in mature T cells, possibly of the CD4 ϩ helper type. Therefore, whereas in the first case we would predict widespread ectopic expression of the transgene, in the second case the CD40L transgene should be expressed in the right cells but in a deregulated way.
Microinjection of the PGK-CD40L fragment yielded three transgenic mice that died shortly after birth. In addition, one live transgenic mouse, which was a mosaic and which did not transmit the transgene to the progeny, was obtained. From the microinjection of the HTLVI-CD40L construct, we obtained two transgenic mice that died perinatally and one viable mouse that was a mosaic but transmitted the transgene to 20% of the progeny. This transgenic lineage was used for further studies. First generation mice were healthy and fertile, and the transgene was transmitted at the expected frequency to the following generations, suggesting that in this lineage, no consistent death in utero occurred.
Northern blot analysis of lymphoid tissues from wt or transgenic animals did not detect any signal derived from the transgenic or endogenous CD40L. This is in agreement with previous findings, as the CD40L is usually not detectable in lymphoid tissues of wt mice by Northern blot analysis. Therefore, we performed an RT-PCR-based expression analysis by designing a forward primer in the HTLVI LTR sequence downstream from the start site and a reverse primer from the CD40L (see Materials and Methods). With this strategy, only the transcripts derived from the transgene should be amplified. A specific PCR product was seen in retrotranscribed RNA from the spleen and thymus of transgenic mice (Fig 1, lanes 1-4) , whereas a transcript from the HPRT locus with appropriate primers was readily detectable in all retrotranscribed samples (Fig 1, lanes  11-14) . Non-retrotranscribed RNAs (Fig 1, lanes 7-10) did not show any amplification of the transgene, as expected.
Clinicopathological findings
At birth, mice appeared healthy. They grew normally and were fertile. However, careful weekly examination Figure 1 . Analysis of the expression of the CD40L transgene: RT-PCR of RNAs extracted from the spleen, liver, thymus, and kidney (lanes 1-4, respectively) from HTLV-CD40L transgenic mice; PCR on the same non-retrotranscribed RNAs (lanes 7-10, respectively); and RT-PCR with HPRT-specific primers performed on the same retrotranscribed samples (lanes 11-14) . Lanes 5 and 6 and lanes 15 and 16 are the positive and negative controls for the CD40L transgene and for HPRT gene expression, respectively. M, marker V (Boehringer Mannheim, Mannheim, Germany).
revealed that at an age ranging from 6 to 12 months, one-third (35 of 105) of the mice had clinically palpable inguinal masses. These enlarged masses did not by themselves affect the health status of these mice, as most of the mice that were sacrificed were apparently in good health. In a few cases, mice became ill and died shortly afterward or were sacrificed.
Extensive histopathological and immunohistochemical analysis was performed on 11 of the 35 mice with clinically detectable masses that underwent necropsy. In two mice, histological examination demonstrated a complete replacement of all lymphoid tissues and diffuse infiltration of visceral organs and soft tissues by a lymphomatous proliferation, with the cytomorphological features of Burkitt's-like lymphoma (Fig 2) . On immunophenotyping (Fig 3) , this cell population was positive for B220 ( Fig 3A) and negative for CD3 (data not shown); CD40 was strongly expressed on the lymphomatous cell population (Fig 3B) , whereas a weak positivity for CD40L was detected only in scattered cells (Fig 3C) .
In the other nine cases examined, most superficial and deep lymph nodes were enlarged, and lymph nodes as large as 1 cm were often present. On morphology, an atypical lymphoid proliferation was observed, characterized by loss of architecture, with marked expansion of macrophage-containing sinuses and of the interposed lymphoid tissue: the lymphoid population was composed of monomorphic medium-sized cells, showing occasional nucleoli and sparse mitoses. Apoptotic nuclei were easily recognizable among these cells, and in one of these cases, the lymphoid population was mitotically active, numerous tingible-body macrophages were admixed, and the overall picture was practically indistinguishable from the proliferation observed in the Burkitt's-like lymphoma. Histological examination of other lymphoid organs (including the thymus, spleen, and mucosa-associated lymphoid tissue) did not reveal major abnormalities. On immunophenotyping, only very rare CD40L ϩ cells were identified.
Finally, it should be noted that in most mice showing either atypical lymphoid proliferation or normal morphology, scattered lymphoid aggregates composed of mature small lymphocytes and plasma cells were observed in the kidneys, lungs, liver portal tracts, and, in two cases, in the salivary glands; in the latter, a peculiar periductal distribution similar to that observed in autoimmune sialoadenitis was found.
Immunological phenotype of the expanding lymphoid population For immunological characterization, cells obtained from grossly enlarged lymph nodes from three different animals were analyzed with specific mAbs. As shown in Figure 4 for the sample obtained from mouse 2809 (atypical proliferation), cells stained positive for HSA, CD45R/B220, and sIg, but were negative for IgM, BP-1, and CD43. This pattern, which was identical in all the three samples examined, is consistent with an expanded mature B-cell population that has performed an Ig class switch. Similar results were obtained in one case of frank lymphoma (mouse 2617), as shown in Figure 4 , suggesting that the neoplastic transformation occurred in the expanded B-cell population detected in the prelymphomatous samples.
Ig gene rearrangement analysis
To confirm this finding and to investigate the clonal nature of the lymphoid populations examined, we analyzed the Ig heavy chain rearrangements in various samples. Genomic DNA extracted from affected lymph nodes and other tissues was digested with EcoRI and analyzed by Southern blot using the joining region pJ11 probe, which detects a 5.8-kb germline band. 49 As shown in Figure 5 , rearranged bands indicative of the presence of a monoclonal population were seen in tissue samples from two different mice histologically diagnosed as having a Burkitt's-like lymphoma (mice 2617 and 2785). The presence of this monoclonal band together with the disappearance of the germline band in nodal samples from mouse 2617 (Fig 5, lane 2) and mouse 2785 (Fig 5,  lanes 4 -6) as well as in the thymus from mouse 2785 (Fig 5, lane 7) suggest that only neoplastic B cells were present in these samples. A residual germline band is seen in the spleen (Fig 5, lane 8) and kidney (Fig 5, lane  3) of mouse 2785, due to the persistence of normal T cells and epithelial cells, respectively. On the contrary, the molecular analysis of three lymph nodes (Fig 5, lanes  10 -12) and the spleen (Fig 5, lane 13) from mouse 2828, which had a histological diagnosis of atypical lymphoid proliferation, showed only the expected germline band also seen in tail DNA (Fig 5, lane 9) .
DISCUSSION
The central finding of this report is the demonstration that deregulated expression of the CD40L in our trans- genic mouse lineage severely perturbs the homeostasis of the lymphoid subsets of lymph nodes. This causes the slow expansion of a B-cell subpopulation that has some features reminiscent of the normal B cells in the GC of secondary follicles. This finding is not unexpected in view of the known biological role of the CD40 system, as it has been demonstrated in mouse models and in HIGM1 patients that CD40/CD40L interaction is not only critical for GC formation 16, 21, 50 but also for GC maintenance. 51 In addition, resting B cells activated in vitro through CD40 and B-cell receptors develop a GC phenotype, 52 and CD40 ligation can save isolated GC B cells from death. 53 Only one of the six founders produced in our lab was viable. In this lineage, the CD40L was placed under the control of regulatory elements of the LTR of the HTLVI, which direct its expression to mature T cells, especially of the CD4 ϩ type. We reasoned that its expression in more immature stages of lymphoid development could have resulted in excessive toxicity, whereas targeting its expression to mature T cells may have been less toxic. Our expression data suggest that this aim has been only partially achieved, as CD40L expression was detected not only in the spleen but also in the thymus. The exact promoter chosen to express CD40L is relevant, as targeting of CD40L to thymus cells resulted in thymocyte depletion and in other inflammation abnormalities, but not in lymphoma. 54 The predominant phenotype in the CD40L transgenic mice occurred at the lymph node level, where a mature B-cell subpopulation, expressing CD45R/B220, sIg, and HSA, was expanded. By immunochemistry, the lymphomatous population was also shown to be CD40
ϩ . Interestingly, no IgM expression was observed, indicating that all B cells had performed Ig class switching. This finding underscores the significance of CD40L in the induction of Ig isotype switching in vivo. The converse phenotype (i.e., failure to produce Ig of isotypes other than IgM in response to Ag challenge) has been observed in HIGM1 patients as well as in CD40 or CD40L knockout mice. The fact that the hyperplastic population appears to be polyclonal, coupled to the CD40 ϩ , IgM Ϫ phenotype, is in agreement with the postulated pathogenesis (i.e., inappropriate activation of GC B cells by a deregulated CD40L). This expanded population of polyclonally rearranged, IgM Ϫ , postfollicular B cells is likely to be susceptible to additional somatic mutations, which may eventually result in the occurrence of tumorigenic B-cell clones. Indeed, the atypical hyperplasia progressed into a frank lymphoma in three cases. However, the real incidence of neoplastic transformation cannot be determined exactly, as most of our mice were sacrificed before 12 months of age. The alternative hypothesis that the neoplastic transformation occurred in T cells due to a direct effect of the deregulated expression of the CD40L transgene is ruled out by the B-cell phenotype of the neoplasias as well as by their negativity for CD40L expression, as determined by immunochemistry studies.
Despite these morphological abnormalities, no clear clinical sign of autoimmune disease was seen in these mice, although some scattered lymphoid aggregates were seen in various tissues, suggesting that abnormal CD40L-mediated B-cell proliferation is not in and of itself sufficient to trigger autoimmune reactions. Therefore, the CD40 pathway cannot be considered completely specular to the Fas system, whose inactivation leads not only to lymphoid proliferation but also to autoimmune phenomena. It is likely that other events such as inappropriate or persistent antigenic stimulation or cytokine secretion are necessary to cause autoimmune phenomena.
A possible mechanism underlying this abnormal proliferation is likely to be a failure of the B cell to undergo apoptosis. CD40-CD40L interaction is usually considered an antiapoptotic stimulus, although to some extent it could also lead to programmed cell death. In this regard, it is interesting that our results are somewhat reminiscent of mice overexpressing bcl-2, whose antiapoptotic effects are well known. A slowly growing lymphoma of follicular B-cell origin is known to occur in humans with chromosomal translocation involving the bcl-2 locus. 55 It is now clear that many genes, in addition to those of the TNF and bcl-2 families, are involved in the establishment and maintenance of the normal lymph node architecture, as disruption of lymph nodes has been also reported with inactivation of bcl-6, 56 cytolytic T-lymphocyte-associated Ag-4, 57 and major histocompatibility complex class II. 58 Recently, a study by Brown et al 59 reported the appearance of T-lymphoproliferative disorders in CD40L Ϫ/Ϫ mice reconstituted with bone marrow cells transduced with a CD40L cDNA under the control of a constitutive promoter. 59 Their study agrees with our report with regard to the main conclusion (i.e., that gene transfer for hereditary defects in tightly regulated genes coding for proteins active on cell proliferation could be dangerous). However, the pathogenesis of the lymphoid neoplasias occurring in the two studies clearly involves different molecular steps. In our study, it seems that deregulated CD40L expression acted on the CD40 ϩ B cells in the lymph node, forcing them to proliferate and switch to IgG production along the physiological pathway used by CD40L ϩ T cells. On the contrary, Brown et al 59 hypothesized that an aberrant interaction between CD40L ϩ , T-cell receptor-␣␤ ϩ , and CD40 ϩ thymocytes was responsible for the genesis of the T-cell lymphoproliferation. It is likely that the different promoters used in the two studies, by targeting transgene expression to different T-cell maturation stages, are responsible for these differences, as our promoter is expected to be most active in peripheral T cells rather than in thymocytes.
Finally, our results are highly relevant to the field of human gene therapy. HIGM1 is a fatal immunodeficiency for which a cure does not exist; therefore, it is a candidate for gene therapy. Several trials have suggested that, although so far ineffective in humans, gene therapy attempts are safe. However, such trials have usually been performed with molecules, mainly enzymes, whose precise regulation is not necessary. Very recently, promising results with retroviral gene transfer in a mouse model of Janus kinase 3 deficiency have been reported, suggesting that reconstitution of immunodeficient patients could be achieved by gene therapy. 60 However, as recognized in this paper and elsewhere, tyrosine kinases of the Janus kinase family, as well as other genes affecting lymphoid cell proliferation, such as cytokines of the TNF superfamily, could have oncogenic effects. 60, 61 CD40L is one of the most tightly regulated genes; it is rapidly induced and then rapidly disappears. In addition to the results reported here, it is noteworthy that a recent study reported in abstract form has shown that 50% of lethally irradiated CD40L knockout mice transplanted with deficient bone marrow transduced with retroviral vectors containing the mouse CD40L gene developed thymic abnormalities, including overt lymphoma. 62 Taken together, these findings suggest that when dealing with gene therapy trials of hereditary diseases in which cytokines or growth factors are involved, additional care has to be taken to avoid excessive stimulation of the target cells.
